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Exposure to a 5-HT1A agonist during late pregnancy affects prepulse 
inhibition in offspring C57BL/6J mice during adulthood
Abstract
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine neurotransmitter, and its effects are mediated via 
5-HT receptors (5-HTRs). Of the several subtypes of 5-HTRs, the 5-HT1A receptor is thought to be involved 
in emotional behaviors and psychiatric disorders. Previous studies have revealed that gene modification and 
the blockade of 5-HT1A receptors during early developmental periods cause anxiety-like behavior later in 
adulthood. However, how abnormal 5-HT1A receptor activation during early developmental stages affects 
emotional behavior remains unclear. In the present study, we examined the effect of transplacental exposure 
to a 5-HT1A agonist [8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide; 8-OH-DPAT] on the behavior of 
offspring during adulthood. Mice exposed to 8-OH-DPAT from embryonic day 14 to parturition showed normal 
development, and showed no difference in locomotion and anxiety- or fear-related behaviors compared to 
saline-exposed mice. However, 8-OH-DPAT-exposed mice exhibited impaired prepulse inhibition in the acoustic 
startle response. These results suggest that excessive activation of 5-HT1A receptors during late pregnancy may 
alter neural development and subsequent information processing.
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Ⅰ. Introduction
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine neurotransmitter thought to be involved in mood- 
and anxiety-related behaviors, as well as in the etiology of psychiatric disorders, such as depression, obsessive 
compulsive disorder, and panic disorder [1]. The effects of 5-HT are mediated via 5-HT receptors (categorized 
into 5-HT1 to 5-HT7) [1]. Among the many 5-HT receptor subtypes, the 5-HT1A receptor has been well studied 
[2]. During the early developmental stage, 5-HT acts as a morphogenic factor, exerting effects on neuronal 
development. For example, a delayed establishment of serotonergic projections to the midbrain and interbrain 
has been observed in both 5-HT1A receptor knockout (5-HT1A KO) and overexpressing (5-HT1A OE) mice [3]. 
5-HT1A KO and 5-HT1A OE mice also show behavioral abnormalities. 5-HT1A KO mice show increased anxiety- 
and stress-like behaviors [4], decreased exploratory behavior, and increased fear-related behavior [5]. In 
contrast, 5-HT1A OE mice exhibit decreased anxiety-like behavior [6]. 
   As the expression of 5-HT1A receptors starts on embryonic days 12 to 14 [2], the disturbance of neural 
transmission via the alteration of 5-HT1A receptors during early maturational periods may affect neural 
development and have subsequent behavioral consequences. Indeed, blockade of 5-HT1A receptors by the 
5-HT1A receptor antagonist WAY-100,653 during early postnatal periods exerts long-lasting effects on anxiety 
[7]. Moreover, knockdown of 5-HT1A receptors in the raphe nucleus of mice during postnatal days (P)14 to 30 
results in increased anxiety and decreased social investigation in adulthood [8]. These results strongly indicate 
that the intact expression and function of 5-HT1A receptors is required for the normal development of emotional 
behavior. Although aberrant 5-HT levels during early developmental stages have been shown to affect the 
emotional behaviors of adults in both humans [9] and animals [10], it is unclear whether abnormal 5-HT1A 
receptor activity during early development affects adult behavior. 
   In the present study, we examined how abnormal 5-HT1A receptor activation during the embryonic period 
influenced adult behavior. For this purpose, we employed a mouse model wherein the embryos were 
continuously exposed to a full 5-HT1A agonist [8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide; 8-OH-
DPAT] via the placenta. 
Ⅱ. Materials and methods
Animals: Six-week-old male (n=5) and female (n=10) C57BL/6J mice were purchased from CLEA Japan, Inc. 
(Tokyo, Japan). Mice were acclimated to the breeding conditions for 1 week, and were then allowed to mate 
(one male and two females per cage). Every morning during the mating period, female mice were manually 
examined for signs of copulation. When copulation was confirmed, females were separated from males and 
individually housed; the day of separation was designated embryonic day 0 (E0). All newborn mice were 
weaned at 4 weeks of age, separated based on sex, and housed with 3–4 littermates per cage. In the present 
study, only male mice were used as subjects. At 10 weeks of age, mice were individually housed for 1 week 
prior to starting the behavioral experiments. The breeding and experiment rooms were air-conditioned (22 ± 
1°C, 50–60% humidity), and the mice were kept on a 12-h light/dark cycle (lights on at 0800). Food and water 
were freely available in the breeding cages. All behavioral experiments, with the exception of home-cage 
activity measurements, were conducted during the light cycle (between 1300 and 1700). All animal experimental 
procedures in the present study were performed in strict accordance with the guidelines of the Institute 
of Physical and Chemical Research (RIKEN), and were approved by the institute’s Animal Investigation 
Committee.
Drug treatment: (±)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT) (Cat. No: 0529: 
TOCRIS, MO, USA) was diluted in physiological saline at room temperature (22 ± 1°C). The final concentration 
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of the drug solution was 3mM. The drug solution was enclosed in an osmic pump (Alzet 1007D, Muromachi 
Kikai, Tokyo, Japan) and administered at a dosage of 1 mg/mouse/week (about 0.1 mg/day). Pregnant female 
mice were anesthetized by intraperitoneal infusion (i.p.) of 2,2,2-tribromoethanol (Avertin) (CAS-No: 75-80-
9, Nacalai Tesque, Kyoto, Japan) solution (1.25%, 300 μl/mouse)1), and pumps were subcutaneously implanted 
into the lower part of the neck. Female mice were kept warm in their home cages until awakening. The time 
course of drug exposure and the experimental schedule is summarized in Figure 1.
Behavioral assessment: Behavioral assessment began when mice were 11 weeks of age. Behavioral 
examinations were conducted as previously described [10, 11], and consisted of the following procedures: 24-h 
home-cage activity measurement for 1 week, open field test [in a 50 (W) × 50 (D) × 40 (H) cm white plastic 
arena] for 15 min, light-dark box test [in a 20 (W) × 20 (D) × 20 (H) cm, white and black box with a 3 × 5 cm 
sliding door in the center panel] for 10 min, elevated plus maze test [closed arms: 25 (W) × 5 (D) × 15 (H) cm; 
open arms 25 (W) × 5 (D) × 0.3 (H) cm; center platform: 5 × 5 cm] for 5 min, acoustic startle response (ASR) 
and prepulse inhibition (PPI) measurement, and classical fear conditioning (consisting of conditioning, context, 
and cued testing phases). 
   For ASR and PPI measurements, each mouse was placed into a small plastic tube (30 or 35 mm in diameter 
and 12-cm-long) that was set on a vibration sensor block in a sound-proofed chamber [60 (W) × 50 (D) × 67 
(H) cm]. A dim light was fixed on the ceiling of the chamber (10 Lux at the center of the sensor block), and 
continuous 65-dB white noise was provided as background noise. The mice were acclimatized to the plastic 
tube and experimental environment for 5 min before the experimental session began. The experimental session 
consisted of an initial startle measurement, a startle threshold measurement, a prepulse inhibition test, and a final 
startle measurement. During the initial startle measurement, a 120-dB startle stimulus (40 ms) was presented 10 
times with a random inter-trial interval (10–20 s). During the startle threshold measurement, the startle responses 
to stimuli presented at various intensities were assessed. Each of the white noise stimuli (70, 75, 80, 85, 90, 95, 
100, 110, and 120 dB; 40 ms) were presented five times in a quasi-random order, and with random inter-trial 
intervals (10–20 s). During the prepulse inhibition test, the mice experienced five types of trials: no stimulus, 
startle stimulus only (120 dB, 40 ms), prepulse 70 dB and pulse 120 dB, prepulse 75 dB and pulse 120 dB, and 
prepulse 80 dB and pulse 120 dB. The prepulse duration was 20 ms, and the lead time (duration between the 
beginning of the prepulse and the beginning of the pulse) was 100 ms. Each type of trial was presented 10 times 
in a quasi-random order with random inter-trial intervals (10–20 s). During the final startle measurement, only 
a 120-dB startle stimulus (40 ms) was presented 10 times with random inter-trial intervals (10–20 s). The total 
duration of the ASR and PPI test was approximately 40 to 45 min.
   Data collection and analysis were conducted using Image J OF4 (open field test), Image J LD4 (light-dark 
box test), Image J EPM (elevated plus maze test), Mouse Startle (ASR and PPI), and Image J FZ2 (classical fear 
conditioning test). All apparatus and software used are commercially available (O’Hara, Tokyo, Japan). Each 
test was conducted after intervals of 1 to 7 days. 
Statistical methods: Statistical analyses were conducted using SPSSTM version 19 statistical software (Japan 
IBM, Tokyo, Japan) and Excel Statistics version 5.0 statistical software for non-parametric statistics (Esumi, 
Tokyo, Japan). A Student’s t-test was used to compare continuous data, and a Mann-Whitney U-test was used to 
analyze the ratio data. Repeated testing paradigms were analyzed using a repeated measures analysis of variance 
1） The side effects of Avertin have been demonstrated, and Avertin is no longer recommended for use in anesthetizing 
animals. This research was conducted before these guidelines were set. 
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[ANOVA; general linear model (GLM)]. When Mauchly's hypothesis of sphericity was not supported, degrees 
of freedom were modified using the Greenhouse-Geisser method [12]. Bonferroni’s method was used for 
multiple comparisons between groups. Differences with a p < 0.05 were deemed statistically significant. 
Ⅲ. Results
Mice exposed to 8-OH-DPAT from embryonic day 14 to parturition (PD0) showed normal body weight and 
development throughout the experiment. Behavioral assessments revealed that both activity and anxiety levels 
were not altered by drug exposure: home-cage activity measurement (total: t=-0.880, p>0.05), open field test 
(distance traveled: t=0.303, p>0.05; total center time: t=-0.599, p>0.05), light-dark box test (distance traveled: 
t=-0.751, p>0.05; % time in light box: U=45, p>0.05), and elevated plus maze test (distance traveled: t=0.153, 
p>0.05; % time open arms: U=32.5, p>0.05). Drug-exposed mice also showed no abnormalities in contextual 
and cued fear memory function in a classical fear conditioning test (context test: U=49, p>0.05; cued test: U=30, 
p>0.05). Results are summarized in Table 1.
   In the ASR and PPI test, no differences were observed in the initial and final startle measurement between 
drug- and saline-exposed mice (main effect of drug: F(1, 18)=0.001, p=0.976; main effect of repeat: F(1, 
18)=0.363, p=0.554; drug x repeat interaction: F(1, 18)=1.454, p=0.244; data not shown). There were also no 
differences in the startle threshold measurement (main effect of drug: F(1, 18)=0.064, p=0.803; main effect of 
repeat: F(2.539, 45.708)=96.609, p=0.000; drug x repeat interaction: F(2.539, 45.708)=0.735, p=0.515; Figure 
2A). On the other hand, there were statistically significant differences in the PPI between drug- and saline-
exposed mice (main effect of drug: F(1, 18)=4.933, p<0.05; main effect of repeat: F(2, 36)=37.142, p=0.000; 
drug x repeat interaction: F(2, 36)=2.869, p=0.070; Figure 2B). Drug-exposed mice exhibited significantly 
lower percent (%)PPI in 70 dB (F(1, 18)=5.401, p<0.05) and 75 dB (F(1, 18)=5.365, p<0.05) prepulse (PP) 
conditions, but showed almost identical %PPI in the 80 dB condition (F(1, 18)=0.123, p=0.73, Figure 2B). 
 
Ⅳ. Discussion
In the present study, we examined the effect of 5-HT1A activation during the late embryonic stage on behavior 
during adulthood. For this purpose, we continuously exposed embryos to the 5-HT1A agonist 8-OH-DPAT 
via an osmotic pump implanted in the dam. The drug was infused at a constant rate from embryonic day 14 
to parturition. However, unlike previous studies that have used 5-HT1A-gene-modified mice or early 5-HT1A 
blockade, our results revealed that drug-exposed mice did not show any alterations in anxiety- or fear-related 
behaviors on examination with standard home-cage activity measurements, or open field, light-dark box, 
elevated plus maze, and classical fear conditioning tests (Table 1). Although drug-exposed mice exhibited 
normal startle responses and startle thresholds, they showed largely impaired prepulse inhibition at both low (70 
dB) and intermediate (75 dB) prepulse intensities (Figure 2). The C57BL/6J strain of mice has been reported to 
display hearing loss with advancing age [13]. However, the mice used in the present study were not old enough 
to have hearing loss, and mice exposed to drugs showed normal fear responses to auditory stimuli in the classical 
fear conditioning test, as well as normal startle responses and startle thresholds in the ASR test. Therefore, as 
the hearing ability was thought to be intact, hearing loss could not explain the PPI deficiency observed in drug-
exposed mice. 
   PPI of the auditory startle response, which is defined as a reduction in the ASR after a weak prepulse stimulus, 
provides an operational measure of sensorimotor gating. PPI has been observed in both rodents and humans [14, 
15]. Moreover, as impaired PPI has been observed in patients as well as in pre-symptomatic individuals with 
schizophrenia and other mental disorders, it is recognized as an important experimental model for the etiology 
and treatment of schizophrenia [16]. Previous studies have suggested a relationship between PPI and 5-HT1 
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receptors using both pharmacological and genetic models [17]. For example, pharmacological studies have 
shown that administration of the 5-HT1A agonist 8-OH-DPAT increases PPI in mice, while the 5-HT1B agonist 
anpirtoline induces PPI deficits. However, 5-HT1A-KO mice do not show alterations in PPI, whereas 5-HT1B-
KOs show some PPI impairment [17, 18]. Inconsistency among these results may, at least in part, be attributable 
to strain-related differences in the levels of 5-HT and/or 5-HT1 receptors [19]. As the 5-HT1A KO mice used 
in the previous studies had 129Sv [18] and Swiss-Webster [4] backgrounds, studies using genetically modified 
mice with a C57BL/6J background are required. 
   The present study is preliminary, and therefore, only limited interpretations can be derived. Nevertheless, our 
findings are meaningful, and suggest that 5-HT1A activation during the late embryonic period could influence 
behavior and information processing in adulthood. Furthermore, the drug-treated mice used in this study have 
the potential to provide a new model to study the prevention of schizophrenia and other mental disorders. 
Previously reported animal models of schizophrenia (e.g., mice treated with the non-competitive NMDAR 
antagonist MK-801 [20] and Zic2 knockdown mice [21]) show abnormal behavior (e.g., hyperlocomotion) that 
is representative of patients with the disorder, and provide useful models for treatment. Although these models 
mimic diagnostic symptoms well, they are not useful models of pre-symptomatic schizophrenia. As the drug-
exposed mice in the present study showed no behavioral abnormalities except for PPI impairment, they could 
prove useful in predicting the onset of mental diseases, as well as for identifying other potential behavioral 
abnormalities. Detailed behavioral analyses as well as anatomical and histochemical evaluations are required to 
establish a new effective model.
Ⅴ. Conclusions
In the present study, we found that sustained activation of the 5-HT1A receptor in embryos during late pregnancy 
altered PPI during adulthood without altering other behaviors. These results suggest that transmission via 
5-HT1A receptors may affect the development of neural circuits related to information processing. Moreover, our 
findings suggest that these mice may provide a new experimental model that can be used for further studies on 
the prevention and treatment of mental diseases. 
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Figure 1 Summary of the time course to the experiment. 
 P: postnatal Day/Week, SC: subcutaneous administration, SAL: physiological saline
Figure 2 Results of the startle threshold measurement (A) and prepulse inhibition test (B).
  AU: arbitrary unit, %inhibition = {1- (startle response with prepulse/startle response to 120dB 
stimulus)}*100,
 Data represent mean ± S.E.M. (A), Data represent mean + S.E.M. , *: p<0.05 (B)
Experimental group
Control group
Gestation (E0) Embryonic (E) Day 14
Continuous SC to dam
(SAL)
P11 weeks
Behavioral analysis start
Behavioral analysis start
Parturition (P0)
Continuous SC to dam
(8-OH-DPAT: 0.1mg/day)
B
0
10
20
30
40
50
60
PP70dB PP75dB PP80dB
Saline
8OHDPAT
%
 in
hi
bi
tio
n
*
*
A
M
ea
n 
Sc
or
e 
(A
U
)
0
0.5
1
1.5
2
2.5
70 75 80 85 90 95 100 110 120
Saline
8OHDPAT
Stimulus Intensity (dB) Condition
Table 1  Summary of the behavioral assessment
saline 8-OH-DPAT statistics
HC activity (mean of 6 days) (count*1) 744.3 810.1 t=-0.880, p>0.05
Open field
distance traveled (cm) 7261.6 7135.13 t=0.303, p>0.05
total center time (sec) 191.1 202.3 t=-0.599, p>0.05
Light-dark box
distance traveled (cm) 2495.0 2589.7 t=-0.751, p>0.05
% time (light box) 297.9 291.2 U=45, p>0.05
Elevated plus maze
distance traveled (cm) 967.5 948.1 t=0.153, p>0.05
% time (open arms) 30.1 17.0 U=32.5, p>0.05
Classical fear conditioning
(% time freezing)
context test 30.1 27.6 U=49, p>0.05
cued test (with tone cue) 20.7 34.3 U=30, p>0.05
*1) arbitrary unit: count 4 – 5 times per sec. 

